Lung Adenosquamous Carcinoma — Variants & evidence

Lung Adenosquamous Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
DDR2 L239R1
Dasatinib	Predictive	D	Supports Sensitivity Response	4	accepted	EID270 The HCC-366 lung adenosquamous carcinoma cell line, containing the DDR2 L239R mutation was shown to be sensitive (IC50 140nm) to dasatinib in-vitro. The authors were unable to establish tumors using t… (full text at CIViC) PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic
ERBB2 Y772_A775DUP1
Afatinib	Predictive	D	Supports Sensitivity Response	4	accepted	EID1047 Human HER2 with YVMA insertion was put under a clara cell specific, rtTA promoter system inducible via doxycycline. Induction of mutant HER2 in these mice drove rapid development of adenosquamous lung… (full text at CIViC) PMID 19122144 · Perera et al., 2009 · Open in CIViC	civic
MET Exon 14 Skipping Mutation1
(prognostic)	Prognostic	C	Supports Poor Outcome	2	submitted	EID11411 A 33-year old male patient (non-smoker) was diagnosed with Stage IVB adenosquamous lung carcinoma. Various treatment strategies were tried but all had progressive disease quickly after treatment. Next… (full text at CIViC) PMID 33854337 · Jiao et al., 2021 · Open in CIViC	civic

Data updated 22 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.